A new study shows that TIL therapy, a personalized immunotherapy using a patient's own immune cells, significantly improves ...

OU Health Stephenson Cancer Center in Oklahoma City has started offering tumor-infiltrating lymphocyte (TIL) therapy as a ...

Patients with advanced melanoma experienced high response rates when treated with commercial Amtagvi in a real-world clinical ...

Daniel Kirby, Chief Commercial Officer of Iovance, stated, “The real world Amtagvi data with impressive response rates, paired with unprecedented five-year durability and survival data, demonstrate a ...

The FDA approved Scancell's phase 3 trial of iSCIB1+ for advanced melanoma, focusing on progression-free survival as a ...

LOS ANGELES -- Patients with metastatic melanoma have faced grim prospects: the American cancer society says the five-year survival rate is only 15 percent. That started changing when the FDA approved ...

In the first multicenter retrospective study of the tumor-infiltrating lymphocyte (TIL) therapy, there was an overall response rate (ORR) of 44% among 41 treated patients, with higher responses in ...

Rick Schneider is a family man — a husband and doting father to three girls. He's also an outdoorsman who loves to bike, hike and ski. There's no mountain he's not ready to climb. But a few years back ...

Before a wrestling tournament in early 2020, Samuel Gee, then 15, underwent a skin check to make sure he didn’t have ringworm that could spread to others. During the inspection, a referee pointed ...

Various agents are being tried in combination with pembrolizumab for the treatment of advanced melanoma in an attempt to improve the response to pembrolizumab. As noted in this previous Reading Room ...